journal article·2017-07-04Open access

Screening of process variables using Plackett–Burman design in the fabrication of gedunin-loaded liposomes

Anil Kumar Sahu, Vishal Jain

Abstract

This study is to screening the formulation and process variables that produce significant effect on the gedunin-loaded liposome formulations by using quality-by-design approach. Placket-Burman screening design was used to screen the most influencing formulation and process variables. Mean vesicle size, zeta potential, entrapment efficiency, and loading capacity were found in the range of 112-990 nm, -19.39 to -39.20 mV, 45.25-87.60%, and 3.54-10.47%, respectively. Differential scanning calorimetry (DSC) and powder X-ray diffraction (XRD) result suggested that Gedunin encapsulated within liposome as amorphous state. The analysis of Pareto chart represented that selected independent variables had a most significant effect on dependent variables.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Phytochemical compounds biological activities · Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, University Institute of Pharmacy, Affiliated by Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, India

References (32)

Show source-provided references
1. 10.1016/j.lwt.2014.04.05810.1016/j.lwt.2014.04.058 ↗
2. 10.1016/j.addr.2012.09.03710.1016/j.addr.2012.09.037 ↗
3. Awada RS · Int J Pharm Pharm Sci · 2015 · 7 · 171
4. 10.1021/jm800748610.1021/jm8007486 ↗
5. 10.1208/s12249-010-9563-010.1208/s12249-010-9563-0 ↗
6. 10.1016/j.colsurfb.2011.07.03610.1016/j.colsurfb.2011.07.036 ↗
7. 10.1016/j.jpba.2011.04.02310.1016/j.jpba.2011.04.023 ↗
8. 10.1016/j.addr.2011.09.00610.1016/j.addr.2011.09.006 ↗
9. 10.1016/j.intimp.2012.06.00210.1016/j.intimp.2012.06.002 ↗
10. 10.1016/S0378-5173(98)00092-110.1016/S0378-5173(98)00092-1 ↗
11. Gradauer K · Int J Nanomed · 2012 · 7 · 2523
12. 10.1208/s12249-015-0337-610.1208/s12249-015-0337-6 ↗
13. 10.1016/j.ejps.2012.07.00610.1016/j.ejps.2012.07.006 ↗
14. International Conference on Harmonization of Technical requirement for registration of pharmaceuticals for human use, ICH harmonizes tripartite guideline, “quality risk management”, Q9 step 4. 2005.
15. Jones R. · Pharm Eng · 2009 · 29 · 1
16. Kuchekar AB · Int J Pharm Pharm Sci · 2014 · 6 · 489
17. 10.1016/j.phymed.2009.10.01610.1016/j.phymed.2009.10.016 ↗
18. 10.1155/2014/35169310.1155/2014/351693 ↗
19. 10.1007/s00436-011-2380-x10.1007/s00436-011-2380-x ↗
20. 10.1080/1094291070164811510.1080/10942910701648115 ↗
21. Pandey G · Int J Pharm Pharm Sci · 2014 · 6 · 444
22. 10.1016/j.reactfunctpolym.2014.02.00210.1016/j.reactfunctpolym.2014.02.002 ↗
23. 10.3109/21691401.2014.95510510.3109/21691401.2014.955105 ↗
24. Pramely R · J Biochem Tech · 2012 · 3 · 375
25. 10.1016/j.foodchem.2015.12.06110.1016/j.foodchem.2015.12.061 ↗
26. 10.1248/bpb.29.19110.1248/bpb.29.191 ↗
27. 10.1155/2014/68939110.1155/2014/689391 ↗
28. 10.1016/j.powtec.2012.10.05510.1016/j.powtec.2012.10.055 ↗
29. 10.1016/j.ijpharm.2008.04.00410.1016/j.ijpharm.2008.04.004 ↗
30. 10.1016/j.colsurfb.2012.06.01310.1016/j.colsurfb.2012.06.013 ↗
31. 10.1016/j.nano.2009.09.00510.1016/j.nano.2009.09.005 ↗
32. 10.1016/j.biomaterials.2014.03.01710.1016/j.biomaterials.2014.03.017 ↗